Your browser doesn't support javascript.
loading
EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.
Giustini, Nicholas P; Pritchard, Colin C; Kamat, Nikhil V; Menon, Manoj P.
Affiliation
  • Giustini NP; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
  • Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
  • Kamat NV; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
  • Menon MP; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
JCO Precis Oncol ; 8: e2300215, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38991179
ABSTRACT
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acrylamides / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Aniline Compounds / Lung Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acrylamides / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Aniline Compounds / Lung Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article Country of publication: United States